Gut-derived lipopolysaccharides (LPS) are critical to the development and progression of chronic low-grade inflammation and metabolic diseases. In this study, the effects of probiotics Lactobacillus and Bifidobacterium on gut-derived lipopolysaccharide and inflammatory cytokine concentrations were evaluated using a human colonic microbiota model. Lactobacillus reuteri, L. rhamnosus, L. plantarum, Bifidobacterium animalis, B. bifidum, B. longum, and B. longum subsp. infantis were identified from the literature for their anti-inflammatory potential. Each bacterial culture was administered daily to a human colonic microbiota model during 14 days. Colonic lipopolysaccharides, and Gram-positive and negative bacteria were quantified. RAW 264.7 macrophage cells were stimulated with supernatant from the human colonic microbiota model. Concentrations of TNF-α, IL-1β, and IL-4 cytokines were measured. Lipopolysaccharide concentrations were significantly reduced with the administration of B. bifidum (-46.45 ± 5.65%), L. rhamnosus (-30.40 ± 5.08%), B. longum (-42.50 ± 1.28%), and B. longum subsp. infantis (-68.85 ± 5.32%) (p < 0.05). Cell counts of Gram-negative and positive bacteria were distinctly affected by the probiotic administered. There was a probiotic strain-specific effect on immunomodulatory responses of RAW 264.7 macrophage cells. B. longum subsp. infantis demonstrated higher capacities to reduce TNF-α concentrations (-69.41 ± 2.78%; p < 0.05) and to increase IL-4 concentrations (+16.50 ± 0.59%; p < 0.05). Colonic lipopolysaccharides were significantly correlated with TNF-α and IL-1β concentrations (p < 0.05).
Gut-derived lipopolysaccharides (LPS) are critical to the development and progression of chronic low-grade inflammation and metabolic diseases. In this study, the effects of probiotics Lactobacillus and Bifidobacterium on gut-derived lipopolysaccharide and inflammatory cytokine concentrations were evaluated using a human colonic microbiota model. Lactobacillus reuteri, L. rhamnosus, L. plantarum, Bifidobacterium animalis, B. bifidum, B. longum, and B. longum subsp. infantis were identified from the literature for their anti-inflammatory potential. Each bacterial culture was administered daily to a human colonic microbiota model during 14 days. Colonic lipopolysaccharides, and Gram-positive and negative bacteria were quantified. RAW 264.7 macrophage cells were stimulated with supernatant from the human colonic microbiota model. Concentrations of TNF-α, IL-1β, and IL-4 cytokines were measured. Lipopolysaccharide concentrations were significantly reduced with the administration of B. bifidum (-46.45 ± 5.65%), L. rhamnosus (-30.40 ± 5.08%), B. longum (-42.50 ± 1.28%), and B. longum subsp. infantis (-68.85 ± 5.32%) (p < 0.05). Cell counts of Gram-negative and positive bacteria were distinctly affected by the probiotic administered. There was a probiotic strain-specific effect on immunomodulatory responses of RAW 264.7 macrophage cells. B. longum subsp. infantis demonstrated higher capacities to reduce TNF-α concentrations (-69.41 ± 2.78%; p < 0.05) and to increase IL-4 concentrations (+16.50 ± 0.59%; p < 0.05). Colonic lipopolysaccharides were significantly correlated with TNF-α and IL-1β concentrations (p < 0.05).
These findings suggest that specific probiotic bacteria, such as B. longum subsp. infantis, might decrease colonic lipopolysaccharide concentrations, which might reduce the proinflammatory tone. This study has noteworthy applications in the field of biotherapeutics for the prevention and/or treatment of inflammatory and metabolic diseases.
Key words: Lactobacilli, bifidobacteria, probiotics, cytokine, lipopolysaccharide, inflammation Gut-derived lipopolysaccharides (LPS) are critical to the development and/or progression of a variety of human conditions, such as chronic low-grade inflammation [5] , metabolic diseases [5, 6, 8] , and liver diseases [1, 34] . LPS are potent immunomodulatory components derived from the cell wall of Gram-negative bacteria [28] , which can translocate to the blood circulation [28] . The immune recognition of LPS is mediated through the cluster of differentiation-14 / toll-like receptor-4 receptor complex in epithelial cells of the intestine and immune cell types, predominantly macrophages, B cells, and dendritic cells [12, 28, 43, 45 ]. An intracellular signaling cascade is subsequently promoted, leading to the secretion of proinflammatory cytokines, such as interleukin (IL)-4, IL-1β and tumor necrosis factor (TNF)-α [5, 33] . IL-4, IL-1β, and TNF-α have all been linked with the initiation and/or maintenance of metabolic diseases [9] .
In addition, substantial evidence has demonstrated that gut dysbiosis [25, 34, 46] might be responsible for increased endotoxemia [37] , which further induces chronic low-grade inflammation [5, 33] and participates in the pathophysiology *Corresponding author Phone: +1-514-398-3676; Fax: +1-514-398-7461; E-mail: satya.prakash@mcgill.ca of metabolic [5, 6, 8] and liver [1, 34] diseases. The manipulation of the gut microbiota composition to reduce endotoxemia and prevent and/or treat human diseases has already been performed [6-8, 17, 18, 40, 50] . Studies using antibiotics to selectively eliminate Gram-negative bacteria have reported significant decreases in cecal and plasma LPS concentrations [6, 17, 18] . Strategies based on the use of prebiotics have demonstrated normalized low-grade inflammation and improved glucose tolerance. Those effects were associated with increased gut bifidobacterial content [7, 8] . Interestingly, recent studies have suggested that probiotic supplements might reduce endotoxemia and chronic lowgrade inflammation [40, 50] . However, to our knowledge, there have been no previous studies examining the effect of probiotics Lactobacillus and Bifidobacterium on gutderived LPS and inflammatory cytokines.
The most widely used probiotic bacteria belong to Bifidobacterium and Lactobacillus spp. Those species have been largely investigated for their health promoting properties in human diseases where gut dysbiosis is inferred to play a pathogenic role. They are assumed to re-equilibrate the gut microbiota composition towards health promoting bacterial populations [40, 50] . Among many hypothesized mechanisms of action, Bifidobacteria and Lactobacilli have been extensively studied for their immunomodulatory activities [13-15, 19, 22, 24, 27, 29, 30, 32, 35, 36, 39, 41, 47-49] . Bacterial cells and components interact with a wide variety of cells present in the intestines, such as epithelial, dentritic, and macrophage cells, which further induce the secretion of pro-and anti-inflammatory cytokines [4, 10, 11, 24, 27, 29, 39, 49] . Frequently, in vitro studies are performed using bacterial cultures exposed to intestinal cell lines, such as intestinal epithelial cells-6 [4], Caco-2 cells [4] , and RAW 264.7 macrophage cells [10, 11] . Those studies are useful to investigate the immunomodulatory properties of bacterial preparations from a pure bacterial culture. However, they neglect the effects induced in the existing gut microbiota.
In this study, we investigated the effect of probiotics Lactobacillus and Bifidobacterium on colonic LPS and inflammatory cytokine concentrations, using an established model of human colonic microbiota [38] and RAW 264.7 macrophage cell lines.
MATERIALS AND METHODS

Bacterial Cultures and Growth Conditions
Probiotic bacteria tested were identified from the literature for their anti-inflammatory potential ( A human colonic microbiota model was set up. After inoculation with fresh human feces, a model stabilization period of 14 days was performed. From day 0, Lactobacillus or Bifidobacterium probiotic strains were administered daily to the human colonic microbiota model. A control fermentation system was performed without administration of probiotic bacteria. Statistical analysis was analyzed to determine the effect of time vs. day 0. On days 0, 7, and 14, samples were extracted from the colonic model for quantification of colonic LPS and Gram-negative/positive bacterial concentrations. RAW 264.7 macrophage cells were stimulated with bacterial supernatant extracted from the colonic model. Positive and negative controls consisted of RAW 264.7 cells exposed to, respectively, 2 µg/ml LPS, and DMEM supplemented with 10% FBS. Concentrations of TNF-α, IL-1β, and IL-4 cytokines were measured.
